Green Lifescience

At a glance

Green Lifescience filed 39 disclosures in the last 12 months, including 3 contract, 3 buyback, 1 insider and 1 5% holder. The most recent key filing was on Jul 31.

Revenue for 2025 was ₩40.3B, up 62.3% on 2024. Operating margin was 0.5% against 1.5% a year earlier. Debt was 43% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩34.6B and operating profit of ₩2.4B.

The 2025 annual report lists 63 employees with an average tenure of 13.3 years and average pay of ₩66.6M, #702 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩74M each on average. It paid no cash dividend for 2025. (주)관악상사 and related parties held 26.81% at year end.

From the 2025 annual report

Staff: 63 (54 men, 9 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩4.2B. Directors and auditors: 4, paid ₩305M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)관악상사 holds 13.00%; with 2 related parties the group holds 26.81% of common shares at year end (from 26.00% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary